LBPH News and Press, Longboard Pharmaceuticals Inc. From 01/05/22

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will presen...

SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the appointment of Jane Tiller, MBChB, FRCPsych, to it...

SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will partic...

Successfully completed multiple ascending dose (MAD) portion of a Phase 1 clinical trial for LP352, a potential treatment for seizures associated with a broad range of severe epilepsies Initiating a Phase 1b/2a clinical trial evaluating LP352 in approximately 50 participants...

SAN DIEGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will ...

The following slide deck was published by Longboard Pharmaceuticals, Inc. in conjunction with this event. For further details see: Longboard Pharmaceuticals (LBPH) Investor Presentation - Slideshow

Favorable safety, tolerability, pharmacokinetics and pharmacodynamics were observed Central 5-HT2c receptor engagement demonstrated by dose- and exposure-dependent increases of prolactin Company plans to initiate a Phase 1b/2a clinical trial in adult particip...

You can read full article here. Drop here! For further details see: Wall Street Breakfast: The Week Ahead (Podcast)

SAN DIEGO, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Kevin R. Lind, Longboard’s President &...

Continued progress with the multiple ascending dose (MAD) portion of the Phase 1 clinical trial for LP352, a potential treatment for severe epileptic indications, with topline results expected in 2021 Initiated a number of IND-enabling preclinical studies for LP143 and LP659...